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Abstract: The synthesis of new isomeric ellipticine quinones 3a-c and their in vitro antiproliferative activities on cancer cell lines is 
reported. The designed N-heterocyclic quinones 3a-c were synthesized through a three step sequence which involves: a) one-pot preparation 
of 4-methoxycarbonyl-3,4-dimethylisoquinoline-5,8-quinone 1 from 2,5-dihydroxyacetophenone, methyl aminocrotonate and silver (II) 
oxide; b) regioselective amination of 1 with arylamines to give aminoquinones 2a-c and c) palladium-catalyzed intramolecular oxidative 
coupling of 7-aminoisoquinoline-5,8-quinones 2a-c. The in vitro antiproliferative activity of the new angular quinones was evaluated againts 
one normal cell line (lung fibroblasts) and gastric, lung and bladder cancer cell lines in 72-h drug exposure assays. The new compounds 
displayed similar or higher antiproliferative activity with respect to their quinone precursors 2a-c. The isomeric ellipticine quinone 2b 
appears as the more active member on  bladder cancer cell line (IC50: 2.4 µM),  comparable to etoposide used as anticancer reference drug. 
 
Keywords: Ellipticine; quinones; oxidative coupling; antiproliferative activity 
  
Resumen: Se describe la síntesis de las nuevas quinonas 3a-c, isoméricas de elipticina, y sus actividades antiproliferativas in vitro en líneas 
de células de cáncer. Las quinonas N-heterocíclicas 3a-c se sintetizaron a través de una secuencia que involucra: a) preparación de 4-
metoxicarbonil-3,4-dimetlisoquinolin-5,8-quinone 1 a partir de 2,5-dihidroxiacetofenona, aminocrotonato de metilo y óxido de plata (I); b) 
aminación regioselectiva de 1 con arilaminas para producir las aminoquinonas 2a-c y c) acoplamiento oxidante intramolecular de 7-
aminoisoquinolin-5,8-quinonas 2a-c catalizado con paladio. La actividad antiproliferative in vitro de los nuevos compuestos fue evaluada en 
una línea celular normal (fibroblastos de pulmón) y líneas de células de cáncer gástrico, pulmón y vejiga en ensayos de exposición de 72 
horas a la droga. Las quinonas 3a-c exhiben interesantes propiedades antiproliferativas  destacando la elipticinquinona isomérica 2b en 
células de cáncer de vejiga (IC50: 2.4 µM) comparado con etopósido usada como droga anticancer de referencia. Los nuevos compuestos 
mostraron actividades antiproliferativa similar o mayor respecto de las correspondientes quinonas precursoras 2a-c. La elipticin quinona 
isomérica 2b corresponde al miembro más activo en células de câncer de vejiga (IC50: 2.4 µM), comparable a la del etopósido, usada como 
droga anticáncer de referencia. 
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INTRODUCTION 
Quinone moieties are present in many drugs such as 
doxorubicin, mitomycin, mitoxantrone, and 
saintopin, which are used clinically in the therapy of 
solid cancers. Anticancer quinones are currently the 
focus of intensive research because of their biological 
activity and complex modes of action, which differ 
depending on their particular structure. A number of 
natural and synthetic heterocyclic quinones have 
important biological activities such as antitumoral, 
antiprotozoan, and antibiotic activities
 
(Tsizin et al., 
1978; Bass et al., 2013). Many of these compounds 
possess antineoplastic chemotherapeutic properties 
(Kock et al., 2005). Among them, carbazolequinone 
alkaloids (Figura 1) exhibit notable biological 
properties such as cardiotonic, antituberculosis, and 
neuronal cell-protecting activities (Shin-Ya et al., 
1997; Kazumi et al., 1989; Knölker et al., 2003; Choi 
et al., 2006; Choi et al., 2008). Pyrido- and 
quinolinocarbazole alkaloids (Figure 1) are also well-
known for their wide range of potent biological 
activities (Gribble et al., 1990; Knölker et al., 2008). 
Ellipticine (5,11-dimethyl-6H-pyrido[4,3- b]carba-
zole) and 9-methoxyellipticine (Figure 1) were 
isolated from the leaves of Ochrosia elliptica Labill 
by Goodwin (Goodwin et al., 1959). The biological 
activity of ellipticine was considered to be based 
mainly on DNA intercalation and topoisomerase II 
inhibition. The first clinical success of celiptium 
(Figura 1) (Juret et al., 1978; Paoletti et al., 1980; 
Dodion et al., 1982; Juret et al., 1982; Clarysse et al., 
1984) led to extensive studies into the synthesis of 
ellipticinium derivatives, and several of these 
progressed to clinical trials (Rouesse et al., 1985; 
Ohashi & Oki, 1996). Since the commercialization of 
some ellipticine derivatives and their successful 
clinical uses prompted tremendous development in 
the chemistry and biology of pyridocarbazole 
alkaloids. 
 
 
 
Figure 1 
Structure of ellipticine and some analogues 
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Ellipticine quinone (Gribble et al., 1984; 
Kecha et al., 1985; Bennasar et al., 2005) is a pivotal 
synthetic intermediate in the early Gribble syntheses 
of ellipticines that shows antitumor activity 
(Bernardo et al., 2004). 
The only known quinolino[4,3-b]carbazole 
alkaloid, calothrixin B (Figure 1) (7H-indolo[3,2-
j]phenanthridine-7,13(12H)-dione), was first obtained 
from a blue-green algae Calothrix cyanobacteria in 
1999 (Rickards et al., 1999). It is a pentacyclic 
quinone that exhibits antimalarial activity as well as 
activity against human HeLa cancer cells and 
inhibition of RNA polymerase (Chen et al., 2003; 
Khan et al., 2009). 
Based on the above precedents and recent 
results in the high yield synthesis of antiproliferative 
phenylaminoisoquinoline-5,8-quinones endowed with 
in vitro topoisomerase I inhibition ability 
(Valderrama et al., 2009; Monsalve et al., 2012), we 
were interested to synthesize new isomeric ellipticine 
quinones to evaluate their in vitro antiproliferative 
activity on a panel of three cancer cell lines.  
 
MATERIALS AND METHODS 
General 
All reagents and solvents were commercially 
available reagent grade. Melting points were 
determined on a Stuart Scientific SMP3 apparatus 
and are uncorrected. 
1
H-NMR spectra were recorded 
on Bruker AM-200 and AM-400 instruments in 
CDCl3 + DMSO-d6. 
13
C-NMR spectra were obtained 
at 50 and 100 MHz in CDCl3 + DMSO-d6. Chemical 
shifts are expressed in δ ppm downfield relative to 
TMS, and the coupling constants (J) are reported in 
Hertz. The HRMS were obtained on a Thermo 
Finnigan spectrometer, model MAT 95XP. Silica gel 
Merck 60 (70–230 mesh) was used for preparative 
column chromatography, and TLC aluminum foil 
60F254 for analytical TLC.  
 
Chemistry 
Synthesis of 1,3-Dimethy-l-4-methoxycarbonyl-
isoquinoline-5,8-quinone 1:  
A suspension of 2,5-dihydroxyacetophenone (1.0 
mmol), silver(II) oxide (2.2 mmol), and MgSO4 (1g) 
and dichloromethane (25 mL) was stirred for 1 h. 
Silver (II) oxide (2.2 mmol) was added to the mixture 
and the stirring was continued for 90 min.  The 
mixture was filtered and the solvent was removed to 
yield crude quinone 1 (231 mg, 94%) which was 
chromatographed on silica gel (9:1 
dichloromethane/ethyl acetate) to yield pure quinone 
1 (74%). 
 
Synthesis of 7-aminoisoquinolinequinone 
derivatives 2a-c:   
A suspension of quinone 1 (1 mmol), the required 
arylamine (2 mmol), CeCl3.7H2O (0.05 mmol), and 
ethanol (20 mL) was left with stirring at rt after 
completion of the reaction as indicated by TLC. The 
reaction mixture was partitioned between 
chloroform/water, the organic extract was washed 
with water (2 x 15 mL), dried over Na2SO4, and 
evaporated under reduced pressure. The residue was 
column chromatographed over silica gel 
(CH2Cl2/ethyl acetate 90:10) to yield the 
corresponding aminoquinones 2a, 2b and 2c in 93%, 
89% and 90% yield respectively. The spectral 
properties of the compounds 2a-c (
1
RMN, 
13
C RMN) 
were comparable with those previously described for 
these compounds (Valderrama et al., 2006). 
 
Synthesis of pyrido[3,4-b]carbazole-5,11-dione 
derivatives 3a-c: 
A suspension of the aminoisoquinolinequinone 2a, 
2b or 3c (1 mmol), Pd(OAc)2 (1,2 mmol) and glacial 
acetic (5mL) was refluxed under nitrogen atmosphere 
after completion of the reaction as indicated by TLC. 
The reaction mixture was cooled, neutralized with 
solid sodium hydrogencarbonate and filtered. The 
filtrate was diluted with water (20 mL) and then 
extracted with ethyl acetate (2 x 15 mL). The organic 
extract was chromatographed on silica gel (CH2Cl2) 
to give the pyrido[3,4-b]carbazole-5,11-dione 
derivatives 3a-c.   
 
Methyl 1,3-dimethyl-5,11-dioxo-10,11-dihydro-5H-
pyrido[3,4-b]carbazole-4-carboxylate 3a:  
Orange solid (60% yield),  mp 108.5-110C; IR: vmax 
3317 (NH), 1725 (C=O), 1652 (C=O quinone); 
1
H 
RMN (400 MHz, CDCl3 + DMSO-d6): 2.62 (s, 3H, 
3-Me), 3.08 (s, 3H, 1-Me), 4.10 (s, 3H, CO2Me), 7.43 
(m, 2H, arom.), 7.50 (d, J = 8.0 Hz, 1H, arom.), 8.26 
(d, J = 8.0 Hz, 1H, arom.), 9.62 (s, 1H, NH). 
13
C 
NMR (400 MHz, CDCl3 + DMSO-d6):  22.7, 26.0, 
53.0, 113.8, 116.9, 121.7, 123.2, 124.1, 124.3, 125.8, 
127.2, 138.0, 138.5, 139.5, 160.0, 160.6, 169.6, 
178.7, 178.7. HRMS (APCI): [M+] calcd for 
C19H14N2O4: 334.09536; found: 334.09484. 
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Methyl 7-methoxy-1,3-dimethyl-5,11-dioxo-10,11-
dihydro-5H-pyrido[3,4-b]carbazole-4-carboxylate 
3b:  
Red solid (53% yield),  mp 233-234C; IR: vmax 3283 
(NH), 1726 (C=O), 1667 and 1657 (C=O quinone); 
1
H RMN (400 MHz, CDCl3 + DMSO-d6):  2.61 (s, 
3H, 3-Me), 3.02 (s, 3H, 1-Me), 3.89 (s, 3H, OMe), 
4.10 (s, 3H, CO2Me),  7.06 (d, J = 9.0 Hz, 1H, arom), 
8.38 (d, J = 9.0 Hz, 1H, arom), 9.45 (s, 1H, NH). 
13
C 
NMR (400 MHz, CDCl3 + DMSO-d6):  22.8, 30.9, 
53.4, 55.8, 103.2, 114.2, 116.9, 119.9, 121.9, 125.3, 
126.0, 132.6, 137.3, 139.3, 157.9, 160.5, 160.9, 
169.7, 178.1, 178.8. HRMS (APCI): [M+] calcd for 
C20H16N2O5: 364.10593; found: 364.10522. 
 
Methyl 6,9-dimethoxy-1,3-dimethyl-5,11-dioxo-
10,11-dihydro-5H-pyrido[3,4-b]carbazole-4-
carboxylate 3c:  
Purple solid (49% yield),  mp 245.5 - 247.5 C; IR: 
vmax 3424 (NH), 1727 (C=O), 1668 and 1659 (C=O 
quinone); 
1
H RMN (400 MHz, CDCl3 + DMSO-d6): 
 2.94 (s, 3H, 3-Me), 3.33 (s, 3H, 1-Me), 3.83 (s, 3H, 
OMe), 3.90 (s, 3H, OMe), 3.93 (s, 3H, CO2Me), 6.67 
(d, J = 8.6 Hz, 1H, arom), 6.88 (d, J = 8.6 Hz, 1H, 
arom), 8.26 (s, 1H, NH). 
13
C NMR (400 MHz, CDCl3 
+ DMSO-d6):  22.1, 26.0, 53.0, 56.5, 56.7, 104.9, 
108.1, 116.3, 125.9 (2C), 130.9, 138.5 (2C), 142.1, 
149.3, (2C), 159.4, 159.9, 169.2, 176.6, 178.1. 
HRMS (APCI): [M+] calcd for C21H18N2O6: 
394.11649; found: 394.11533. 
 
Electrochemical Measurement (Prieto et al., 2007) 
Cyclic voltammograms of compounds were obtained 
on a Bioanalytical Sytem BAS CV-50W 
electrochemical analyzer. A small capacity 
measuring cell was equipped with a platinum disc as 
working electrode, an Ag/10 nM Ag (MeCN) 
reference electrode for non aqueous solvent, with a 
platinum wire auxiliary electrode, a mechanical mini-
stirrer, and a capillary to supply an inert argon 
atmosphere. A 0.1 M solution of tetrabutyl-
ammonium tetrafluoroborate in acetonitrile was used 
as supporting electrolyte. 
 
Anticancer assay (Rodríguez et al., 1999) 
The cell lines used in this work were obtained from 
the American Type Culture Collection (ATCC, 
Manasas, VA, USA). They included MRC-5 normal 
human fibroblasts (CC-171), AGS human gastric 
adenocarcinoma cells (CRL-1739), SK-MES-1 
human lung cancer cells (HTB-58, and J82 human 
bladder carcinoma cells (HTB-1). After the arrival of 
the cells, they were proliferated in the corresponding 
culture medium as suggested by the ATCC. The cells 
were stored in medium containing 10% glycerol in 
liquid nitrogen. The viability of the cells after 
thawing was higher than 90% assessed by trypan blue 
exclusion test. Cells were sub-cultured once a week 
and medium was changed every two days. Cells were 
grown in the following media: MRC-5, SK-MES-1, 
and J82 in MEM, and AGS cells in Ham F-12. The 
MEM medium contained 2 mM L-glutamine, 1 mM 
sodium pyruvate, and 1.5 g/L sodium 
hydrogencarbonate. Ham F-12 was supplemented 
with 2 mM L-glutamine and 1.5 g/L sodium 
hydrogencarbonate. All media were supplemented 
with 10% heat-inactivated FBS, 100 IU/mL 
penicillin, and 100 µg/mL streptomycin in a 
humidified incubator with 5% CO2 in air at 37 °C. 
For the experiments, cells were plated at a density of 
50,000 cells/mL in 96-well plated. One day after 
seeding, the cells were treated with the medium 
containing the compounds at concentrations ranging 
from 0 to 100 µM during 3 days, and finally the MTT 
reduction assay was carried out. The final 
concentration of MTT was 1 mg/mL. The compounds 
were dissolved in DMSO (1% final concentration) 
and complete medium. Untreated cells (medium 
containing 1% DMSO) were used as controls. Each 
experiment was carried out in sextuplicate. 
 
RESULTS AND DISCUSSION 
We explore the access to isomeric ellipticine 
quinones from phenylaminoisoquinolinequinones by 
using a well-documented carbazolequinone synthetic 
method based on the palladium-catalyzed 
intramolecular oxidative coupling reaction of 
arylamino-1,4-quinones (Akerman et al., 1975). This 
method has been successfully employed for the 
synthesis of ellipticine and related alkaloids from 
diarylamines (Miller & Mook, 1980; Motoi et al., 
1991; Knölker & Fröhener, 1998). The entry to the 
target isomeric ellipticine quinones 3a-c was planned 
from aminoisoquinoline-5,8-quinones 2a-c by using 
the palladium-catalyzed oxidative coupling reaction. 
The elected aminoisoquinoline-5,8-quinones 2a-c   
were prepared from isoquinolinequinone 1 which in 
turn was synthesized through a previously reported 
one pot procedure from  2,5-dihydroacetophenone, 
methyl aminocrotonate and silver (II) oxide 
(Valderrama et al., 2006). Scheme 1 outlined the 
reaction sequence to prepare the ellipticine quinones 
3a-c.  
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The oxidative cyclization of 2a to 
pyridocarbazolquinone 3a was examined by using 
stoichiometric amounts of Pd(OAc)2 in glacial acetic 
acid at reflux. After several trials the cyclization 
products 3a-3c were isolated in 60, 53 and 49% 
yields respectively.   
The structure of the new compounds 3a-c 
were fully established by mean of their 
1
H/
13
C NMR 
and high resolution mass spectra.  
 
 
 
Scheme 1 
Synthesis of isomeric ellipticine quinones 3a-c 
 
 
 
 
 
 
 
The redox potentials of compounds 3a-c 
were measured by cyclic voltammetry in acetonitrile 
as solvent, at room temperature, using a platinum 
electrode and 0.1 M tetraethylammonium 
tetrafluoroborate as the supporting electrolyte (Prieto 
et al., 2007). All compounds show two one-electron 
reduction waves to form the corresponding anion-
radical and dianion. The first half-wave potential 
values, E
I
1/2, evaluated from the voltammograms, are 
summarized in Table 1. The data indicate that the 
E
I
1/2, values for the first electron, which is related 
with the formation of the semiquinone radical anion, 
are in the potential range 578-624 mV. Comparison 
of the half wave potentials of 3a and 3b with those of 
their respective precursors 2a and 2b indicate that 
reduction of the products are located at a more 
positive region with respect to their precursors. The 
results revealed that the donor-acceptor interactions 
between the isoquinolinequinone nucleus (acceptor) 
and the arylamine group (donor) in 2a and 2b is more 
favorable than that of the acceptor with the fused 
indole fragment in compounds 3a and 3b. In the case 
of quinone 3c and its precursor 2c it was observed 
that the interaction of the acceptor with their 
respective donors is more favorable in 3c than 2c.  
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Table 1 
Electrochemical potentials of compounds 2a-c and 3a-c. 
  
Structure  Compound R
1
 R
2
 R
3
 -E
I
1/2  (mV) 
 
2a H H H 592 
2b H OMe H 622 
2c OMe H OMe 573 
 
3a H H H 578 
3b H OMe H 588 
3c OMe H OMe 624 
 
The newly synthesized isomeric ellipticine 
quinones 3a-c were evaluated for their in vitro 
anticancer activities against human normal cell: 
MRC-5 human lung fibroblasts and three human 
tumor cells: AGS gastric adenocarcinoma, SK-MES-
1 lung cancer, and J82 bladder carcinoma, in 72 h 
drug exposure MTT assays. Etoposide, a clinically 
used anticancer agent, was used as a positive control. 
The antiproliferative activity of the compounds was 
measured using a conventional microculture 
tetrazolium reduction assay (Scudiero et. al., 1988; 
Van de Loosdrecht et al., 1994). The antiproliferative 
activities by each of the heterocyclic quinones are 
expressed in terms of IC50 (Table 2). The previously 
reported antiproliferative activity of 
arylaminoisoquinolinequinone 2a-c were included in 
Table 2 together with those of their cyclization 
products 3a-c to get information on the differences in 
the antiproliferative activity as consequence of the 
eventual redox cycling and/or DNA-binding 
biological mechanism. 
 
 
Table 2 
Antiproliferative activity of isomeric ellipticine quinones 3a-c and its precursors 2a-c 
 
 
 
                                                                                                                            IC50 (µM)
a 
N° R
1 
R
2 
R
3 MRC-5
b
 AGS
c
 SK-MES-1
d
 J82
e
 
2a H H H 5.6 2.1 4.2 5.8 
2b H OMe H 9.0 2.3 7.2 7.4 
2c OMe H OMe 31.3 19.9 >100 >100 
3a H H H 2.4 1.2 3.9 2.9 
3b H OMe H 2.5 2.4 7.5 2.4 
3c OMe H OMe >100 38.6 33.9 >100 
- Etoposide   3.9 ± 0.2 0.36 ± 0.02 2.5 ± 0.2 2.8 ± 0.2 
a Data represent mean average values for six independent determinations. 
b Human lung fibroblasts cells. 
c Human gastric adenocarcinoma cell line. 
d Human lung cancer cell line. 
e Human bladder carcinoma cell line. 
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The screening showed that compounds 3a-c 
exhibit significant antitumor activity in the range 
IC50: 1.2-38.9 µM. As indicated in Table 2, the 
antitumor activity of compounds 3a and 3b on 
bladder cancer cells were comparable to that shown 
by the reference drug etoposide (IC50 = 2.8 µM). 
Comparison between the IC50 and E
I
1/2 values, 
indicate that for compounds 3a and 3b, the more 
positive the E1/2 (respect to compounds 2a and 2b) 
the stronger the antitumor promoting effect on AGS, 
J82 and SK-MES-1 cell lines. On the contrary, 3b 
shows less cytotoxic activity in all the cell lines 
compared to 2b. Analyses of the data revealed that 
the first reduction potential E1/2 is an important 
parameter determining the antitumoral activity on 
AGS gastric adenocarcinoma, SK-MES-1 lung 
adenocarcinoma and J82 bladder carcinoma cell 
lines. 
 
CONCLUSIONS 
In conclusion, we have described preliminary results 
on the synthesis and antiproliferative evaluation of 
three new isomeric ellipticine quinones The new 
quinones expressed moderate to high in vitro 
antiproliferative activity against three human cancer 
cell lines: AGS (gastric), SK-MES-1 (lung) and J82 
(bladder) cell lines. Compound 3b appears as a 
promising active compound against bladder cancer 
cell line, with IC50 value at 2.4 µM, comparable to 
that of the anti-cancer agent etoposide. 
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